Final analysis of a phase II trial of daratumumab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma without transplant

Final analysis of a phase II trial of daratumumab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma without transplant

We evaluated the efficacy and safety of 24 cycles of Dara in combination with carfilzomib (K), lenalidomide (R), and dexamethasone (d) without autologous stem cell transplant (ASCT) in newly diagnosed multiple myeloma (NDMM) irrespective of ASCT eligibility in a single-arm, phase II study. The prima...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Blood cancer journal (New York) 2024-05, Vol.14 (1), p.87-9, Article 87
Hauptverfasser: Derman, Benjamin A., Cooperrider, Jennifer, Rosenblatt, Jacalyn, Avigan, David E., Rampurwala, Murtuza, Barnidge, David, Major, Ajay, Karrison, Theodore, Jiang, Ken, Ramsland, Aubrianna, Kubicki, Tadeusz, Jakubowiak, Andrzej J.
Format: Artikel
Sprache:eng
Schlagworte:
13/1
14
631/67/1990/804
692/308/2779/109/1941
82/16
82/58
Adult
Aged
Antibodies, Monoclonal - administration & dosage
Antibodies, Monoclonal - therapeutic use
Antineoplastic Combined Chemotherapy Protocols - adverse effects
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Biomedical and Life Sciences
Biomedicine
Cancer Research
Dexamethasone - administration & dosage
Dexamethasone - therapeutic use
Female
Hematology
Humans
Immunotherapy
Lenalidomide - administration & dosage
Lenalidomide - adverse effects
Lenalidomide - therapeutic use
Male
Middle Aged
Multiple myeloma
Multiple Myeloma - diagnosis
Multiple Myeloma - drug therapy
Multiple Myeloma - mortality
Neoplasm, Residual
Oligopeptides - administration & dosage
Oligopeptides - therapeutic use
Oncology
Targeted cancer therapy
Treatment Outcome
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:We evaluated the efficacy and safety of 24 cycles of Dara in combination with carfilzomib (K), lenalidomide (R), and dexamethasone (d) without autologous stem cell transplant (ASCT) in newly diagnosed multiple myeloma (NDMM) irrespective of ASCT eligibility in a single-arm, phase II study. The primary endpoint was the rate of stringent complete response (sCR) and/or measurable residual disease (MRD) 
ISSN:2044-5385
2044-5385
DOI:10.1038/s41408-024-01045-3